These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15716701)

  • 1. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation.
    Fratta Pasini A; Garbin U; Nava MC; Stranieri C; Davoli A; Sawamura T; Lo Cascio V; Cominacini L
    J Hypertens; 2005 Mar; 23(3):589-96. PubMed ID: 15716701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ
    Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation.
    Cominacini L; Fratta Pasini A; Garbin U; Nava C; Davoli A; Criscuoli M; Crea A; Sawamura T; Lo Cascio V
    J Am Coll Cardiol; 2003 Nov; 42(10):1838-44. PubMed ID: 14642697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ; Castillo R; Rodrigo R; Prieto JC; Aramburu I; Brugere S; Galdames K; Noriega V; Miranda HF
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G; Trevano FQ; Facchini A; Toutouzas T; Chanu B; Mancia G
    Blood Press Suppl; 2003 Dec; 2():35-40. PubMed ID: 14761075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
    Zanchetti A
    Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction.
    Pires MJ; Rodríguez-Peña AB; Arévalo M; Cenador B; Evangelista S; Esteller A; Sánchez-Rodríguez A; Colaço A; López-Novoa JM
    J Hypertens; 2007 Dec; 25(12):2486-96. PubMed ID: 17984671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
    Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
    Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tempol-nebivolol therapy potentiates hypotensive effect increasing NO bioavailability and signaling pathway.
    Bertera FM; Santa-Cruz DM; Balestrasse KB; Gorzalczany SB; Höcht C; Taira CA; Polizio AH
    Free Radic Res; 2014 Feb; 48(2):109-18. PubMed ID: 24074298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebivolol alleviates aortic remodeling through eNOS upregulation and inhibition of oxidative stress in l-NAME-induced hypertensive rats.
    Wang Y; Zhang F; Liu Y; Yin S; Pang X; Li Z; Wei Z
    Clin Exp Hypertens; 2017; 39(7):628-639. PubMed ID: 28640644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
    Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
    Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients.
    Taddei S; Virdis A; Ghiadoni L; Magagna A; Pasini AF; Garbin U; Cominacini L; Salvetti A
    J Hypertens; 2001 Aug; 19(8):1379-86. PubMed ID: 11518845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
    Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
    J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats.
    Wang Y; Zhang M; Liu Y; Liu Y; Chen M
    Vascul Pharmacol; 2011; 54(1-2):36-43. PubMed ID: 21167314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study.
    Redón J; Pascual-Izuel JM; Rodilla E; Vicente A; Oliván J; Bonet J; Torguet JP; Calaforra O; Almirall J
    Blood Press; 2014 Jun; 23(3):181-8. PubMed ID: 24059690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension].
    Tuncer M; Fettser DV; Gunes Y; Batyraliev TA; Guntekin U; Gumrukchuoglu KhA; Eryonucu B; Guler N; Sidorenko BA
    Kardiologiia; 2008; 48(4):42-5. PubMed ID: 18447840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
    Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
    Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
    J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.